These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 16670396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J.
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):601-8. PubMed ID: 18383442
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 10. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul 04; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Jul 04; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.
    Curr Med Res Opin; 2006 Jan 04; 22(1):199-210. PubMed ID: 16393445
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.
    Drug Saf; 2005 Jan 04; 28(9):803-16. PubMed ID: 16119973
    [Abstract] [Full Text] [Related]

  • 20. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 04; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.